Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113491 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL30327955 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL145251 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL794147 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL120496 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL145249 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL2745491 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| SCHEMBL24062219 | 0.96 | ALDH1A1 (0.37) | ALDH1A1HSD17B10KDM4EEPHX1 | |
| Hydrochloric Acid SCHEMBL4083778 | 0.96 | ALDH1A1 (0.30) | ALDH1A1HSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL31511693 | 0.96 | ALDH1A1 (0.30) | ALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119894509-A | Sodium channel blocking compounds, derivatives thereof, and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-12103921-B2 | Chemical compounds | PFIZER INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240252506-A1 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| WO-2010094120-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2010071741-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008119773-A1 | AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES | MEDIVIR AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008060391-A2 | 2- [L-PHENYL-5-HYDR0XY-4ALPHA-METHYL-HEXAHYDR0CYCL0PENTA[F] INDAZ0L-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-7335791-B1 | Process for the synthesis of hydroxy aromatic acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111856-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | ALDH1A1 2556/4885HSD17B10 841/4885KDM4E 3337/4885 |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CCR9, CCR1, CCR2 | ALDH1A1 2024/4885HSD17B10 3467/4885KDM4E 3353/4885 |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | ALDH1A1 1862/4885HSD17B10 707/4885KDM4E 4755/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | ALDH1A1 3132/4885HSD17B10 3775/4885KDM4E 454/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | ALDH1A1 1862/4885HSD17B10 707/4885KDM4E 4755/4885 |
| US-12103921-B2 | Chemical compounds | HBZ, HBB, HBS1L | ALDH1A1 1737/4885HSD17B10 1652/4885KDM4E 2745/4885 |
| US-20240252506-A1 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | ALDH1A1 630/4885HSD17B10 3053/4885KDM4E 4324/4885 |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, NR5A1 | ALDH1A1 1742/4885HSD17B10 1069/4885KDM4E 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.